Literature DB >> 2544183

Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417.

E Multon1, J F Riou, D LeFevre, J C Ahomadegbe, G Riou.   

Abstract

Ellipticine derivatives have been shown to induce DNA strand breaks by trapping DNA-topoisomerase II (Topo II) in an intermediary covalent complex between Topo II and DNA which could be related to their cytotoxic effects. We report here that Celiptium and Detalliptinium, two ellipticine derivatives clinically used for their antitumoral properties against breast cancer, exhibit the highest in vitro activity on Topo II DNA cleavage reaction and decatenation among a series of 14 ellipticine derivatives. The in vitro cleavage site specificity in pBR 322 plasmid DNA and in a human c-myc gene inserted in a lambda phage DNA is identical for both ellipticines, but different from m-AMSA, another Topo II related antitumoral agent. Recently, it has been shown that the ellipticine derivative Celiptium presents a strong cytotoxic activity in vitro on different human tumors including small cell lung carcinoma (SCLC). However, the studies that involved Topo II as a target for ellipticine derivatives have been performed only by using animal tumor cell lines. Therefore we have studied the in vivo DNA cleavage activity of Celiptium and Detalliptinium on a human SCLC cell line, NCI N417, comparatively to that obtained with m-AMSA. The respective IC50 on cell growth are 9, 8 and 1 microM for Celiptium, Detalliptinium and m-AMSA, respectively. Using the alkaline elution technique, we have observed that Celiptium and Detalliptinium exhibit a weak cleavage activity on genomic DNA from whole cells. The ellipticines are about 50 times less potent than m-AMSA in inducing DNA strand breaks. Analysis of in vivo c-myc gene cleavage by Southern blot hybridization also demonstrates a lack of activity of the ellipticine derivatives as no gene cleavage could be detected up to 50 microM of the drug. With m-AMSA, c-myc gene cleavage is detected at a concentration of 0.2 microM, which indicates that this methodology is less sensitive in detecting DNA strand breaks than is the alkaline elution. Further studies of the drug effect on isolated nuclei by alkaline elution also show that the DNA cleavage activity of Celiptium and Detalliptinium is increased when compared to whole cells. Our data indicate that these two drugs have a weaker cytotoxic effect than m-AMSA on NCI N417 cell line, due to a limited access to the cell nucleus rather than to a lack of activity on Topo II as assessed by in vitro and isolated nuclei experiments.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2544183     DOI: 10.1016/0006-2952(89)90060-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Mechanism-based common reactivity pattern (COREPA) modelling of aryl hydrocarbon receptor binding affinity.

Authors:  P I Petkov; J C Rowlands; R Budinsky; B Zhao; M S Denison; O Mekenyan
Journal:  SAR QSAR Environ Res       Date:  2010-01-01       Impact factor: 3.000

2.  Inhibition of human DNA topoisomerase IIα by two novel ellipticine derivatives.

Authors:  Kendra R Vann; Yavuz Ergün; Sevil Zencir; Serkan Oncuoglu; Neil Osheroff; Zeki Topcu
Journal:  Bioorg Med Chem Lett       Date:  2016-02-15       Impact factor: 2.823

3.  Phase I study of Datelliptium chloride, hydrochloride given by 24-h continuous intravenous infusion.

Authors:  D Khayat; C Borel; M Azab; D Paraisot; E Malaurie; C Bouloux; M Weil
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Ellipticine increases the superhelical density of intracellular SV40 DNA by intercalation.

Authors:  Y Chu; M T Hsu
Journal:  Nucleic Acids Res       Date:  1992-08-11       Impact factor: 16.971

5.  Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73.

Authors:  Chao Lu; Wenge Wang; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2008-12       Impact factor: 4.742

6.  Phase II study of a combination of elliptinium and vinblastine in metastatic breast cancer.

Authors:  L Kayitalire; F Thomas; T Le Chevalier; C Toussaint; T Tursz; M Spielmann
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

7.  Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism.

Authors:  M Ohashi; E Sugikawa; N Nakanishi
Journal:  Jpn J Cancer Res       Date:  1995-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.